XBB.1 omicron subvariant monovalent vaccine (Daiichi Sankyo)

N/A

Report date: 2025/01/26 17:14:32

Base Information

Drug NameXBB.1 omicron subvariant monovalent vaccine (Daiichi Sankyo)
Drug Alias NameSARS-CoV-2 vaccine (omicron variant) (Daiichi Sankyo)monovalent SARS-CoV-2 vaccine (Daiichi Sankyo)monovalent omicron variant vaccine (Daiichi Sankyo)
ClassificationVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A